New research explores the reasons why women turn to alcohol, tobacco, and cannabis during pregnancy
©mstaniewski-stock.adobe.com
New research by Canadian investigators points to depression as the number one risk factor among pregnant women for use of alcohol, tobacco, and cannabis during pregnancy. Policy interventions targeting at-risk women, the authors say, are needed to improve maternal mental health.
Published in The Journal of Neonatal-Perinatal Medicine, the findings are from a retrospective cohort study of more than 25,000 pregnant women from Southwestern Ontario. The data analyzed were extracted from perinatal and neonatal diabetes at tertiary hospital in London, Ontario. Maternal postal codes and a Geographic Information System were used to map neighborhood-level socioeconomic values.
The primary objective of the study was an assessment of relative effects of socioeconomic, demographic, and mental health risk factors associated with substance use in pregnancy. Birth outcomes also were evaluated, using an Apgar score < 7 and fetal macrosomia as secondary outcomes. Separate logistic regressions were computed for all outcome variables.
Rates of use of alcohol, tobacco, and cannabis during pregnancy in the study population were 1.9%, 16.2%, and 2.3%, respectively. The researchers found that depression in pregnancy was associated with a 2.15 times higher risk of use of alcohol (95% CI 1.60-2.90). 1.70 times higher risk of smoking tobacco (95% CI 1.48-1.95), and 2.56 times higher risk of using cannabis (95% CI 1.95-3.35).
Having anxiety also increased the risk of substance use in pregnancy, whereas there was an inverse relationship between maternal age and use of alcohol, tobacco, and cannabis. Looking at outcomes in the neonates, the investigators found that adverse outcomes were associated with maternal overweight and obesity, gestational diabetes, and insulin-dependent diabetes.
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More